View in EDS HTML Full Text PDF Full Text

Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation – diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib.

Saved in:
Bibliographic Details
Title: Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation – diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib.
Authors: Manur, Rashmi1 (AUTHOR), Sung, Pamela J.2 (AUTHOR), Loren, Alison W.2 (AUTHOR), Ritchie, Ellen K.3 (AUTHOR), Frank, Dale4 (AUTHOR), Bagg, Adam4 (AUTHOR), Geyer, Julia T.5 (AUTHOR), Bogusz, Agata M.4 (AUTHOR) Agata.Bogusz@pennmedicine.upenn.edu
Source: Leukemia & Lymphoma. Feb2020, Vol. 61 Issue 2, p450-454. 5p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:10428194
DOI:10.1080/10428194.2019.1660975